Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 857

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7A
Chunk 857
---
 9,930          Loss from Operations  (10,108)  (9,930)         OTHER INCOME        Net change in fair value of trading marketable securities  282   641 Total other income  282   641          Provision for income taxes  -   -          NET LOSS $(9,826) $(9,289)         OTHER COMPREHENSIVE INCOME        Foreign currency translation adjustments  1   51 Total Other Comprehensive Income  1   51          TOTAL COMPREHENSIVE LOSS $(9,825) $(9,238)         Basic and Diluted Loss per Common Share $(3.05) $(3.14)         Basic and Diluted Weighted Average Common Shares Outstanding  3,223   2,960 

The accompanying notes are an integral part of these audited consolidated financial statements.

 F-4Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Stockholders’ Equity

(In thousands)

     Additional     Accumulated Other       Common stock  paid-in  Accumulated  Comprehensive      Shares  Amount  capital  Deficit  Income (loss)  Total                    Balance, December 31, 2022  2,856  $3  $50,675  $(31,021) $(254) $19,403                          Issuance of common shares  333   -   567   -   -   567 Stock based compensation  -   -   1,020   -   -   1,020 Net loss for the period  -   -   -   (9,289)  -   (9,289)Other comprehensive income  -   -   -   -   51   51 Balance, December 31, 2023  3,189  $3  $52,262  $(40,310) $(203) $11,752                          Issuance of common shares  92   -   112   -   -   112 Stock based compensation